- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00866983
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
January 28, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A Local, Multi-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Patients Who Completed A1481244 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil , Prior To Reimbursement And Availability For Patients In Brazil.
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil.
It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 90610-000
- Pfizer Investigational Site
-
-
SP
-
São Paulo, SP, Brazil, 04012-909
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject who completed the A1481244 study and are judged by the Investigator to derive clinical benefit from continuous treatment with Sildenafil 20 mg therapy.
- Subject who resides in a Brazilian State where Sildenafil is not supplied by State Health Secretary.
Exclusion Criteria:
- Pregnant or lactating women.
- Current participation in other studies and during study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
March 20, 2009
First Submitted That Met QC Criteria
March 20, 2009
First Posted (Estimate)
March 23, 2009
Study Record Updates
Last Update Posted (Actual)
February 1, 2021
Last Update Submitted That Met QC Criteria
January 28, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension, Pulmonary
- Hypertension
- Pulmonary Arterial Hypertension
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- A1481270
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on sildenafil (Revatio) 20 mg TID
-
Stanford UniversityAnn & Robert H Lurie Children's Hospital of ChicagoCompletedLymphatic Diseases | Lymphatic MalformationsUnited States
-
PfizerMedivation, Inc.TerminatedAlzheimer DiseaseUnited States, Hungary, Germany, Spain, Turkey, Slovakia, Canada, Portugal
-
Assiut UniversityUnknown
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownPulmonary HypertensionSpain
-
University of Alabama at BirminghamUniversity Teaching Hospital, Lusaka, Zambia; Cameroon Baptist Convention Health and other collaboratorsNot yet recruitingDevelopment, Infant | Neonatal Asphyxia | Intrapartum Fetal Distress | Intrapartum AsphyxiaZambia, Cameroon, Kenya
-
Merck Sharp & Dohme LLCCompleted
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Center for Advancing...RecruitingPediatric Pulmonary HypertensionUnited States, Canada
-
Mirum Pharmaceuticals, Inc.Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...No longer availablePulmonary Arterial HypertensionIndia